|
|
Vol. 14.22 – 13 November, 2025
|
|
|
|
|
|
|
|
The authors identified the transcriptional repressor Capicua (CIC) as a key target inactivated by KRAS/MAPK signaling in lung adenocarcinoma. They showed that genetic loss of CIC recapitulates the phenotypic consequences of amplified KRAS signaling. [EMBO Molecular Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists found that miR-26a knockout mice exhibited reduced pulmonary fibrosis compared with wild-type mice. Loss of miR-26a increases PTEN expression, a target gene of miR-26a, resulting in the reduction of Timp1 levels downstream of the PI3K/Akt-mTOR pathway, thereby attenuating fibrosis.
[Molecular Therapy – Nucleic Acids]
|
|
|
|
|
|
Investigators employed scRNA-seq to profile the transcriptional landscape of the lungs in well-established murine models of sepsis-induced acute lung injury. [Respiratory Research]
|
|
|
|
|
|
|
|
Researchers showed that aging represses oncogenic KRAS-driven tumor initiation and growth in genetically engineered mouse models of human lung cancer.
[Nature Aging]
|
|
|
|
|
|
Scientists observed that circRNA LMNB1 increases the sensitivity of lung adenocarcinoma to osimertinib in vitro and in vivo. [Cell Death & Disease]
|
|
|
|
|
|
Investigators identified mitotic spindle organizing protein 2B (MZT2B) as a critical oncogenic driver and potential therapeutic vulnerability in NSCLC.
[Cell Death & Disease]
|
|
|
|
|
|
Scientists showed that small cell lung cancer (SCLC) cells can form functional synapses with neurons. Synapse-forming SCLC cells reveal a heterogeneous sensitivity to the AMPA receptor antagonist cyanquixaline and are also reduced following GABAA receptor blockade. [Communications Biology]
|
|
|
|
|
|
|
|
The authors synthesize molecular mechanisms that underlie resistance to third-generation EGFR tyrosine kinase inhibitors and discuss emerging approaches to pre-empt resistance through early application of combination therapies.
[Nature Reviews Clinical Oncology]
|
|
|
|
|
|
Scientists summarize distinctive features of the tumor–immune microenvironment in small cell lung cancer and evaluate current immunotherapeutic strategies, notably immune checkpoint inhibitors, that have demonstrated survival benefits in a subset of patients. [Experimental Hematology & Oncology]
|
|
|
|
|
|
|
|
Three University College London (UCL) scientists have been awarded prestigious European Research Council Synergy Grants 2025 to support research into how lung cancer spreads and how the brain controls instinctive behaviors. [UCL]
|
|
|
|
|
|
|
|
December 11-12, 2025 Cambridge, Massachusetts, United States
|
|
|
|
|
|
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|
|
University of Cologne – Cologne, Germany
|
|
|
|
|
|
|
Mayo Clinic – Rochester, Minnesota, United States
|
|
|
|
|
|
|
|
|
Henry Ford Health + Michigan State – Detroit, Michigan, United States
|
|
|
|
|
|